THE GIFT OF LIGHT

SYLVESTER COMPREHENSIVE CANCER CENTER
UNIVERSITY OF MIAMI HEALTH SYSTEM

NCI Designated Cancer Center

2024
Sylvester Impact Report

MOMENTS LIKE THESE ARE WHAT WE LIVE FOR

Only Sylvester offers a degree of personalized cancer care not available anywhere else. We're here for you from diagnosis through every step of survivorship. So, what inspires us to make bold discoveries and deliver superior care? That's easy. It's you. Getting you back to your life and what you love — it's what our team at Sylvester strives for every day.

Sylvester Comprehensive Cancer Center, part of UHealth – University of Miami Health System, is South Florida's only National Cancer Institute (NCI)–designated cancer center.

SYLVESTER COMPREHENSIVE CANCER CENTER
UNIVERSITY OF MIAMI HEALTH SYSTEM

OnlySylvester.com | 844-324-HOPE (4673)

NCI Designated Cancer Center

TOGETHER FOR A BRIGHTER FUTURE

As we reflect on the past year at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine and UHealth — UM's Health System, we are overwhelmed with pride and gratitude. This annual impact report is more than a summary of milestones; it is a testament to the dedication, resilience and vision of our team, our patients and our supporters. Together, we are shaping a future where cancer care and research thrive hand in hand, united by a shared purpose to transform lives.

The past year was transformative for Sylvester, with many landmark achievements.

Among our greatest achievements was the successful renewal of our National Cancer Institute (NCI) designation, reaffirming our standing among the top 4% of cancer centers nationwide and as South Florida's only NCI-designated cancer center.

This prestigious recognition reflects the collective brilliance and hard work of our community, allowing us to expand research, attract vital funding and, ultimately, improve patient outcomes. We were equally inspired by the extraordinary $93 million raised in philanthropy, including a historic $50 million naming gift for the Kenneth C. Griffin Cancer Research Building. These gifts signify trust in our mission and an enduring belief in the transformative power of science and care.

At the heart of Sylvester is a patient-first philosophy. This year, we witnessed a 15% increase in patient volumes, a clear indicator of our growing reach and impact. We expanded our facilities with the establishment of the Sylvester Brain Tumor Institute and the expansion of our Doral site. These efforts bring life-saving care closer to those who need it most. Looking ahead, we remain resolute in our commitment to achieve NCI "Comprehensive" designation in five years, joining an elite group of only 57 institutions nationwide. This goal is not just aspirational; it is a guiding light that shapes our strategic planning and every decision we make.

Our journey forward is already taking shape. With the upcoming launch of SoLé Mia in North Miami, we are poised to expand our offerings and bring hope to even more families. Our dedication to breaking barriers in access, care and outcomes remains unwavering. The Sylvester Retreat this past year underscored this mission. It was a powerful gathering of hundreds of cancer researchers and physicians where we recalibrated our trajectory, reaffirmed our purpose and mapped our strategic goals for the next five years. At the retreat, we set our sights on ensuring that every patient's journey is met with compassion and innovation.

At the forefront of research, Sylvester continues to make groundbreaking strides. Precision medicine remains a cornerstone of our approach, minimizing toxicity and maximizing therapeutic benefits through tailored treatments. We celebrated Dr. C. Ola Landgren's pivotal research on minimal residual disease (MRD) in myeloma, which has the potential to revolutionize drug approval processes and accelerate access to effective therapies. This is just one example of how Sylvester's work is shaping the future of oncology, not just in Miami but globally.

Collaboration is the key to innovation. Our partnerships with other NCI-designated cancer centers amplify our efforts to tackle some of the most challenging cancers, from brain and pancreatic to neuroendocrine and blood malignancies. Additionally, our leadership in lifestyle medicine and cancer survivorship continues to set national benchmarks. The "Celebration of Life" conference this year brought together a record number of cancer-free patients—a poignant reminder of why we do what we do.

As South Florida's population grows, so does Sylvester's role in shaping the health care landscape. The region's vibrant, dynamic economy provides fertile ground for innovation and progress. As part of the University of Miami, we are uniquely positioned to address the needs of our expanding community while honoring the legacy of Harcourt Sylvester Jr., former business executive, philanthropist and the visionary behind the only university-based cancer center in South Florida.

Looking ahead, we are committed to fostering innovation, attracting world-class talent and advancing the frontiers of cancer care and research. The next five years will be pivotal as we strive to achieve new heights in care delivery and scientific discoveries. The future of Sylvester is bright, and it is built on the foundation of collective effort—from our researchers and clinicians to our patients, families and generous supporters, such as the Dolphins Cancer Challenge and The Pap Corps, which help us in our mission.

We invite you to explore the highlights in this report, celebrate our shared achievements, and join us in envisioning the next chapter of Sylvester. Together, we will continue to push the boundaries of what is possible in the fight against cancer.

With unwavering hope and optimism,

Stephen D. Nimer, M.D.
Director
Sylvester Comprehensive Cancer Center

Jayne Sylvester Malfitano
Chair, Board of Governors
Sylvester Comprehensive Cancer Center

LIGHTING THE WAY FORWARD

RESEARCH

141 publications in peer-reviewed journals (Impact Factor >10)

$50M+ in cancer-related federal and state funding

$4M in training grants

99 R01 grants

PATIENTS

52K+ patients served

910K+ outpatient visits

8K+ surgeries

4K+ participants in 456 clinical research studies (interventional and non-interventional)

800+ accruals to interventional treatment trials

270+ accruals to phase I, I/II trials

WORKFORCE

3,525 employees:
606 physicians and physician-scientists
1,010 nurses
1,909 clinical, research and administrative staff

20+ additional, new physician-scientists

1,100+ trainees

COMMUNITIES

10 locations across South Florida + one coordination office in Southwest Florida

55K+ residents across South Florida engaged in 387 cancer community education events

1,300+ people screened for cancer at community events, including 220 Game Changer vehicle community events*
500+ women screened for HPV
400+ men screened for prostate cancer
500 men and women screened for colorectal cancer

*Some individuals received multiple screenings but are counted only once.

DONORS

$103M+ total donations, including a $50M naming gift for the Kenneth C. Griffin Cancer Research Building

30+ donors to the Kenneth C. Griffin Cancer Research Building

3,800+ total donations

1,100+ first-time donors

21 estate gifts

‘OUTSTANDING’ NCI DESIGNATION RENEWAL

Five years after achieving the prestigious National Cancer Institute (NCI) designation, Sylvester, part of the University of Miami Miller School of Medicine, has secured the honor again, receiving an “Outstanding” score from the NCI. This designation, held by only 72 cancer centers in the U.S. in 2024, reflects scientific leadership in research and a commitment to addressing community health challenges with state and national implications.

As one of these elite centers, Sylvester ranks in the top 4% of U.S. cancer centers.

“Our cancer center’s outstanding score for the NCI renewal underscores the unwavering dedication of our entire organization,” said Joe Echevarria, CEO and president of the University of Miami and CEO of UHealth. “I am incredibly proud of Sylvester’s profound impact on cancer research and patient care.”

Sylvester’s renewal solidifies its role as the only NCI-designated cancer center in South Florida. The designation brings access to exclusive clinical trials, benefiting patients across the region. This is especially vital In Florida, which has the nation’s second-highest cancer burden in the U.S.

“We have built something invaluable for our community,” said Sylvester Director Stephen D. Nimer, M.D., who has led the center since 2012. Through teamwork, precision medicine, breakthrough science and compassionate care, we are transforming cancer care in South Florida, he said.

Dipen J. Parekh, M.D., UHealth’s COO, highlighted the renewal’s importance: “The NCI grant underscores our ability to deliver top-tier care and innovative treatments. It’s critical for achieving excellent outcomes and offering hope to patients.”

Since earning its first NCI designation five years ago, Sylvester has expanded its impact with initiatives in experimental therapeutics, survivorship and cutting-edge research. "The renewal of our NCI grant bolsters our cancer center’s research and treatment capabilities and enhances the learning opportunities for our medical students and residents," said Henri R. Ford, M.D., dean of the Miller School. It ensures future professionals are equipped to lead in cancer care and research, he said.

A RIGOROUS REVIEW

Securing NCI designation involves a highly competitive review by approximately 17 nationally recognized experts. Sylvester’s renewal application included a 1,992-page Cancer Center Support Grant (CCSG), supplemented by an in-person site visit.

During the site visit, reviewers evaluated core research programs, cancer metrics and impactful discoveries presented by Sylvester’s research leaders. The center received even better scores for each of Sylvester’s core research programs in Cancer Control, Cancer Epigenetics and Tumor Biology. A newly launched Translational Clinical Oncology program earned an “Outstanding” rating. In addition, Dr. Nimer was recognized with an “Exceptional” rating as director.

Looking ahead to its next NCI-designation application in 2029, Sylvester remains focused on advancing its strategic goals to meet and exceed NCI requirements, ensuring continued leadership in the nation’s pursuit of cancer cures.

SPARK

CURIOSITY

THAT IGNITES

RESEARCH INNOVATION

In 2024, we ignited sparks of hope and discovery, forging transformative advancements in cancer research. With each breakthrough, the center illuminated the path to a future where science and compassion converge to conquer disease.

At the forefront of innovation, Sylvester's Assistant Director of Technology and Innovation, Shanta Dhar, Ph.D., and her team overcame the formidable blood-brain barrier with a novel nanoparticle, delivering dual blows to cancer's energy systems and offering new hope for patients with brain metastases. Building on this innovative mindset and collaborative spirit, Eric Mellon, M.D., Ph.D., a radiation oncologist and co-leader of Sylvester's Neurologic Cancer Site Disease Group, advanced glioblastoma research by using MRI-linac technology to adapt radiation therapy in real time, blending precision with possibility.

Our drive to make lifesaving treatments accessible extended far beyond the lab. Globally, Gilberto Lopes, M.D., examined the cost-effectiveness of durvalumab, an immunotherapy for lung cancer. This work complemented local innovations, including a saliva-based tool from Sylvester researcher Elizabeth Franzmann, M.D., for early cancer detection and a voice-preserving laser surgery technique from Director of the Division of Laryngology and Voice, David Rosow, M.D., for glottic cancer.

Our yearly achievements culminated with our presence at the 66th Annual American Society of Hematology (ASH) Annual Meeting & Exposition, showcasing the center's leadership in hematology research. Through 132 presentations, workshops and special sections, Sylvester's researchers shared leading-edge findings, shaping the future of blood cancer treatment.

Together, these milestones embody our innovative mindset and collaborative spirit, underscoring our unwavering commitment to innovation and quest for cancer cures.

Access Sylvester´s Research.

THE GIFT OF POSSIBILITY:

LIFE'S RENEWED PROMISE

At just 26 years old, LaShae Rolle, a promising Ph.D. candidate at the University of Miami Miller School of Medicine, faced a challenge no one could have predicted. During a self-exam, she discovered a lump in her breast. With no family history of cancer and no other risk factors, she initially thought it was benign. But a visit to Sylvester led to a life-altering diagnosis: multicentric breast cancer, a rare and aggressive form of the disease.

"I had no risk factors," Rolle recalled. "If I had waited until age 45 for screening, I wouldn't have made it." This realization inspired her to advocate for awareness among adolescents and young adults (AYAs) about the importance of self-exams, a practice she credited with saving her life.

Rolle underwent a unilateral mastectomy to remove one breast, chemotherapy and proton radiation. She also faced a tough decision: Should she preserve her fertility? She chose to freeze her eggs but realized others might not have access to similar resources. "I can imagine the loneliness many may experience," she said.

Sylvester's AYA support group became her lifeline, and she joined two clinical trials. Her resilience extended beyond her research work. A former college basketball player turned competitive powerlifter, she now uses social media to inspire others, sharing her fitness journey during treatment.

"My experience gives me a new perspective," she said. "Even though this is terrible now, I want to motivate others and help survivors feel less alone."

TRANSFORMING MYELOMA CARE

C. Ola Landgren, M.D., Ph.D., chief of the Division of Myeloma and director of the Sylvester Myeloma Institute, is revolutionizing multiple myeloma care. His groundbreaking research may speed up drug approval timelines and enhance therapeutic strategies to deliver better outcomes for patients.

In April, a significant milestone occurred when a U.S. Food and Drug Administration (FDA) committee endorsed the use of minimal residual disease (MRD) as a clinical trial endpoint, a decision rooted in Dr. Landgren's EVIDENCE (evaluating minimal residual disease as an intermediate clinical endpoint for multiple myeloma) meta-analysis, which was published in the journal *Blood*.

This shift has the potential to fast-track new treatments and reduce the approval process by years, ultimately benefiting patients.

MRD measures the presence of residual tumor cells with extraordinary precision, providing valuable insights into patient outcomes, such as progression-free survival. Incorporating MRD into the approval process allows the FDA to grant accelerated approval for therapies based on MRD negativity (the absence of detectable cancer cells in a patient's bone marrow), with longer-term survival data needed for full approval. Dr. Landgren's 15 years of MRD research, starting at the National Cancer Institute, has led to better testing methods and fostered collaborations with pharmaceutical companies, advancing the precision of this approach.

A NEW STANDARD OF CARE

At Sylvester, Dr. Landgren continues to pioneer quadruple therapy, a combination regimen including a CD38-targeted monoclonal antibody (such as daratumumab or isatuximab), a proteasome inhibitor, an immunomodulatory drug and a steroid. Results from trials show this regimen's ability to achieve deeper responses, extend progression-free survival and improve overall outcomes. Additionally, quadruple therapy is designed to be tolerable for a broad range of patients, including older adults, improving access to leading-edge treatments.

Dr. Landgren is also advancing precision medicine at Sylvester by combining MRD testing with genomic profiling. This enables personalization of treatments based on individual tumor genetics. This tailored approach is challenging the traditional use of therapies like stem cell transplants, with emerging technologies like CAR T-cell therapy and bispecific monoclonal antibodies potentially replacing them for some patients, for improved outcomes.

BREAKTHROUGH MODEL

Dr. Landgren and his team developed the Individual Risk Model for Myeloma (IRMMa), a revolutionary computational model that helps predict personalized outcomes for newly diagnosed multiple myeloma patients. Published in the *Journal of Clinical Oncology*, IRMMa uses tumor genomics and treatment data to provide more accurate prognoses than previous tools. By analyzing genetic sequences from nearly 2,000 patients, the model identifies 90 "driver genes" linked to tumor growth and correlates these markers with treatment outcomes. Leveraging machine learning, IRMMa improves as more data becomes available, ensuring its dynamic and evolving nature.

Dr. Landgren views IRMMa as a significant advancement in precision medicine, offering a personalized approach that improves outcomes for myeloma patients.

Dr. C. Ola Landgren

INVESTIGATING RISKS

Beyond treatment advancements, Dr. Landgren is investigating the environmental and genetic factors contributing to multiple myeloma. Studies have linked higher levels of monoclonal gammopathy of undetermined significance (MGUS), a precursor to myeloma, to pesticide exposure in farmers, Agent Orange in Vietnam War veterans and toxins at the 9/11 site. Dr. Landgren is co-leading a study with Sylvester Myeloma Institute Associate Director Dickran Kazandjian, M.D., on the risks of myeloma in military officers exposed to burning pits during the Gulf War. The results of this study will shed light on environmental and occupational factors that may increase myeloma risk.

Dr. Landgren's transformative work is reshaping multiple myeloma care. Through innovations like MRD-driven drug approval processes, quadruple therapy and the IRMMa model, he is improving outcomes for myeloma patients. As Sylvester continues to lead in cancer research, Dr. Landgren's ongoing research is helping create a path toward a cure for myeloma.

RESEARCH SHAPING THE FUTURE

Sylvester is making strides in predicting which patients will respond to immunotherapy. In a recent study, tumors were categorized into seven immune subtypes, with one subtype showing improved response to immune checkpoint inhibitors. This breakthrough could help identify patients who are good candidates for immunotherapy and lead to new treatments to make "immune cold" tumors more responsive to therapy. The study combined big data analysis and AI to refine these predictions and improve cancer care. Michele Ceccarelli, a University of Miami professor of computational oncology, co-led the study with co-author Antonio Iavarone, M.D., deputy director of Sylvester.

In the landmark multisite ANCHOR (Anal Cancer HSIL Outcomes Research) study, Sylvester contributed research that led to the release of the first federal guidelines for anal cancer screening in people with HIV. Isabella Rosa-Cunha, M.D., an associate professor in the Division of Infectious Diseases at the Miller School and the initiator of the anal cancer prevention program at Sylvester and Jackson Memorial Hospital, was the principal investigator in Miami and JoNell Efantis Potter, Ph.D., APRN, FAAN, chief of the Women's HIV Service and vice chair of reproductive sciences at the Miller School, was a co-investigator on the ANCHOR study. The study demonstrated that treating anal pre-cancer lesions (HSIL) in HIV-positive individuals can reduce the risk of anal cancer by 60%. These findings directly informed the CDC's new guidelines, which call for regular screening of HIV-positive adults, particularly those over 35, using methods such as anoscopy and lab-based anal "Pap smears."

Steven Chen, Ph.D., a researcher at Sylvester, led a study that identified a 10-gene biomarker that predicts whether stage 2 or stage 3 colon cancer patients will benefit from adjuvant chemotherapy. Using machine learning, the research team developed a model that outperforms previous methods in predicting chemotherapy responses. While still needing clinical trials for validation, this biomarker could enable personalized treatment decisions and even predict responses to immunotherapy.

Sophia George, Ph.D., and Matthew Schlumbrecht, M.D., M.P.H., researchers at Sylvester, are conducting a global study on the ovarian cancer drug niraparib, focusing on women of African descent. The research aims to understand the drug's safety, effectiveness and dosing for African populations. The study spans the U.S., the Caribbean and Nigeria.

Sylvester launched a new study focused on early lung cancer detection in Hispanics, especially those with a history of cancer, who are at three times greater risk of developing cancer. Led by Coral Olazagasti, M.D., a thoracic medical oncologist, Sylvester's study aims to improve screening access and awareness. Early detection through low-dose CT scans can reduce lung cancer mortality, and Sylvester is working to increase participation in this critical screening.

Smoking is linked to DNA mutations and worse outcomes in blood cancers like myelodysplastic syndromes. A study led by Sylvester found smokers had more genetic mutations and higher disease progression rates. The findings highlight the urgency of quitting smoking, even after diagnosis, to reduce mutations and improve survival. Sangeetha Venugopal, M.D., a physician-researcher at Sylvester, is the lead author of the study.

Sylvester conducted a multidisciplinary study on electric vehicle (EV) fires to understand the risks, especially for firefighters and communities. Alberto Caban-Martinez, Ph.D., D.O., M.P.H., deputy director of the Sylvester Firefighter Cancer Initiative (FCI) and professor of public health sciences at the Miller School, led the multidisciplinary, multi-institutional study of EV fires. The team's research focused on toxins released during EV fires, which include heavy metals and gases, and aims to improve safety protocols and public awareness.

In the wake of rising liver cancer rates in the U.S., particularly among Latinos, Sylvester is researching a major risk factor, MASLD (metabolic dysfunction-associated steatotic liver disease). Patricia D. Jones, M.D., Sylvester researcher, hepatologist and associate professor of clinical medicine at the Miller School, and Melissa Lopez-Pentecost, Ph.D., RDN, a post-doctoral research fellow and registered dietitian at Sylvester, are leading studies on how MASLD can lead to fatty liver and cirrhosis. Their research investigates genetic and behavioral factors in Latino populations to improve screening and early detection, focusing on diet, genetics and social factors.

IMMUNOTHERAPY'S NEW DAWN

Jose Lutzky, M.D., an oncologist at Sylvester, is leading efforts in the use of tumor-infiltrating lymphocyte (TIL) therapy for advanced melanoma.

Recently FDA-approved, this cellular therapy harnesses a patient's own immune cells to fight cancer.

Dr. Lutzky emphasized the significant advancement TIL therapy represents, particularly for patients whose melanoma has failed previous treatments. Sylvester is the only South Florida center offering this therapy.

Dr. Lutzky is also involved in a clinical trial testing modified TIL therapy to remove the PD-1 gene, aiming to boost immune cell activity and improve treatment efficacy.

NEW FRONTIERS IN BRAIN CANCER

The research on malignant brain tumors is rising to a whole new level. In 2024, Sylvester launched the **Sylvester Brain Tumor Institute (SBTI)** to advance brain cancer care and research. With a Brain Tumor Initiative for many years that provided research and clinical care, Sylvester moved forward to establish the SBTI to elevate brain cancer care and research in South Florida and beyond.

SBTI's mission is to foster collaboration across multiple disciplines, uniting experts from various fields to tackle glioblastoma and other complex brain cancers. Glioblastoma, a highly aggressive and difficult-to-treat cancer, has a survival rate of just 12 to 18 months, making it a primary focus of the institute.

Under the leadership of Antonio Iavarone, M.D., director, the institute brings together multidisciplinary teams of clinicians, surgeons and scientists to develop personalized treatments.

The team is creating patient-specific laboratory models using biopsied tissue to generate patient-derived organoids and xenografts.

These models allow for detailed studies and drug testing, enabling precision treatments tailored to the unique characteristics of each tumor, thereby enhancing clinical trial outcomes and patient care.

SBTI leadership also includes three co-directors – Macarena de la Fuente, M.D., Ricardo Komotar, M.D., and Anna Lasorella, M.D., who is also director of Sylvester's Precision Medicine Initiative. Together, they lead a comprehensive approach to brain tumor research and treatment.

A key focus of the institute is understanding the evolution of glioblastoma after treatment, specifically how tumors develop resistance and recur.

The Sylvester Brain Tumor Institute leadership team (from left): Dr. Antonio Iavarone, Dr. Macarena de la Fuente, Dr. Anna Lasorella and Dr. Ricardo Komotar

By identifying biomarkers and tailoring therapies accordingly, SBTI aims to offer more personalized, effective treatments and expedite the approval of new therapies.

The establishment of SBTI marks a significant step forward in Sylvester's commitment to improving brain cancer treatment in South Florida, combining leading-edge research, personalized care and clinical innovation to achieve better patient outcomes.

UNMASKING GLIOBLASTOMA RESISTANCE

Collaborative research is also a cornerstone for SBTI, which will continue to build on areas of study. Earlier in the year, a remarkable discovery found that cancer cells are adept at evading treatment by disguising themselves as healthy cells. Glioblastoma, an incurable brain cancer, can mimic human neurons, even growing axons and forming connections with healthy neurons, which contributes to its resistance to drugs.

A study from Sylvester and its collaborators found that this neuron mimicry is key to the cancer's treatment resistance. The researchers also identified a class of therapeutics, BRAF inhibitors, that could prevent tumors from becoming drug-resistant.

Co-led by Dr. Iavarone, the study used a unique platform to analyze glioblastoma cells' proteomes, or complete protein sets. This approach allowed them to spot modifications in proteins that indicate enzyme activity, offering insights beyond genetic data alone.

By studying tumor samples from 123 glioblastoma patients, both at diagnosis and after recurrence, the team created the largest dataset of its kind. This allowed them to identify crucial changes that drive treatment resistance.

The researchers focused on kinases, enzymes that regulate protein activity. Using machine learning, they identified BRAF as a key kinase involved in glioblastoma's resistance. Unlike in other cancers, BRAF protein levels increase in glioblastoma without mutations in the gene itself. This discovery would not have been possible without analyzing the cancer proteome.

Dr. Iavarone hopes this proteomic approach can lead to next-generation precision therapies for glioblastoma and other resistant cancers.

FUNDING PATHWAYS

Researchers at Sylvester, including Lara Traeger, Ph.D., are leading a five-year, $3 million study funded by the National Cancer Institute to address sexual health concerns among bone marrow transplant survivors. The study evaluates SHIFT, a digital app that provides education and guided exercises to support patients facing intimacy challenges after transplant.

Researchers at Sylvester, led by Jashodeep Datta, M.D., assistant director of transdisciplinary research, received a $2.5 million grant from the National Cancer Institute to investigate new treatments for pancreatic cancer. The study focuses on disrupting a protective cellular network that makes tumors resistant to therapy. Findings could lead to clinical trials by 2026, improving survival rates for this deadly disease.

Jay Spiegel, M.D., Peter Hosein, M.D., Jashodeep Datta, M.D., Alejandro Villarino, Ph.D., and Defne Bayik, Ph.D., researchers at Sylvester, are leading V Foundation-funded projects totaling over $1.5 million. Dr. Spiegel combines CAR T-cell therapy with new drugs for B-cell lymphoma. Dr. Hosein and Dr. Datta are studying pancreatic cancer responses to immunotherapy, Dr. Villarino is developing a platform to study T-cell malignancies and Dr. Bayik is advancing glioblastoma research.

Sylvester researchers Sophia George, Ph.D., and Matthew Schlumbrecht, M.D., M.P.H., were awarded two $1 million Department of Defense grants and are leading studies on endometrial cancer in Black women. Their research focuses on genetics, examining populations from the U.S., Caribbean and West Africa. They are also developing awareness programs to address care and symptoms, working with Shakeya Allen, a patient advocate.

Researchers at Sylvester, including Sara Fleszar-Pavlović, Ph.D., Frank Penedo, Ph.D., and Nipun Merchant, M.D., received a $600,000 Department of Defense grant to study an eHealth-based stress management tool for pancreatic cancer survivors. The tool aims to address physical and emotional challenges, enhancing coping skills and reducing stress, potentially improving quality of life for these patients during and after treatment.

For 18 years, the American Cancer Society has supported junior faculty at Sylvester with institutional research grants. These seed grants help young researchers generate early findings to secure larger funding. This year's recipients included Namrata Chandhok, M.D., Emiliano Cocco, Ph.D., Martín Rivas, Ph.D., and Benjamin Spieler, M.D.

Carmen Calfa, M.D., breast cancer medical oncologist, received a grant from the Woman's Cancer Association, which advocates for universal genetic testing to identify inherited cancer-related changes. Her research aims to reduce financial barriers, focusing on promoting early detection and personalized care for future generations.

EVOLUTION OF CLL TREATMENT

Patients with chronic lymphocytic leukemia (CLL) and related blood cancers often receive targeted treatments called BTK (Bruton's tyrosine kinase) inhibitors, which can shrink tumors and extend survival. However, some patients develop resistance to these drugs, limiting their treatment options.

A new study at Sylvester, led by researcher Justin Taylor, M.D., offers a promising solution with a next-generation BTK-targeting therapy that not only inactivates, but actually destroys, the BTK molecule, overcoming drug resistance.

Dr. Taylor and his team tested the new compound, NX-2127, in laboratory studies and a phase 1 clinical trial with patients whose tumors were resistant to previous treatments. The results were promising: The compound destroyed BTK molecules in patient cells and led to tumor shrinkage in 11 out of 14 CLL patients, including those who had developed resistance to approved BTK inhibitors.

NX-2127 is a BTK degrader, a new class of drug that binds to BTK and directs it to the cell's trash heap. Unlike current BTK inhibitors, which inhibit the enzyme, these degraders eliminate the target entirely. The therapy successfully overcomes various mutations in BTK that lead to resistance, a major breakthrough in treatment for CLL patients.

One notable case involved an elderly patient who had developed resistance to previous therapies. After receiving NX-2127, the patient's symptoms improved significantly, and he no longer required blood transfusions for anemia.

These encouraging findings could have broader implications, potentially treating other B-cell malignancies and autoimmune diseases.

Dr. Taylor's team is now enrolling patients in a study testing an even more potent BTK degrader, NX-5948, offering hope for improved treatment options for those battling CLL and similar cancers.

Dr. Taylor is studying compounds that destroy BTK molecules, to overcome drug resistance

SHINE

COMPASSIONATE CARE THAT TRANSFORMS LIVES

We continue to redefine cancer care in South Florida, combining precision medicine, innovative treatments and compassionate support to lead the way in patient care. This holistic approach ensures patients receive the most advanced and personalized care available.

This year, we reached a milestone in the treatment of neuroendocrine tumors, with critical new guidelines unveiled in *CA: A Cancer Journal for Clinicians*. These guidelines provide new advancements in the diagnosis, staging and management of this rare cancer and reflect Sylvester's commitment to leading-edge care. Led by Aman Chauhan, M.D., our Neuroendocrine Tumor Program is setting the standard for treatment, empowering patients with precision tools like theranostics, which combines imaging and radiation therapy to target tumors with remarkable accuracy.

Building on this dedication to innovation, our neurosurgical team demonstrated the power of collaboration and human connection during a unique procedure. In a remarkable surgery, guitarist Christian Nolen became a partner in his own care as he played music during his awake craniotomy. As Ricardo Komotar, M.D., Sylvester Brain Tumor Institute's co-director of surgical neuro-oncology, and his team removed a glioma, Nolen's guitar playing helped guide the surgery to preserve Nolen's dexterity, underscoring the role of personalized care and the art of medicine.

Our commitment to individualized care extends beyond the operating room, as seen in Tracey Hecht's story. Her journey of survival from breast cancer and the BRCA1 gene exemplifies the comprehensive support we provide. The Genetic Predisposition Syndrome Clinic supported Hecht, who navigated 16 rounds of chemotherapy, highlighting that cancer care is not just about treatment, but also about reclaiming life with resilience and hope.

Each breakthrough and story we share reflects tailored attention to every patient's unique needs and our transformative approach to cancer care. Our vision is to treat cancer and empower individuals to shine and embrace life with renewed strength.

View Our Patient Services and Clinical Trials.

THE GIFT OF HEALING:

BEYOND THE CLOUDS

In 2014, 21-year-old Manuel Garcia put his passion for skydiving on hold. With 81 jumps behind him, the cost of gear and the ambition to take up BASE jumping meant that the sky was no longer within reach. But the future had something else in store for him.

Five years later, Garcia's world was turned upside down. He began experiencing excruciating abdominal pain and severe weight loss. Diagnosed with stage 4 metastatic pancreatic cancer, he was given a grim prognosis. The disease had spread to his liver, spine and brain. Doctors weren't sure if chemotherapy or hospice care was the best option.

However, Garcia's determination was unwavering. Under the care of Peter Hosein, M.D., he began a course of chemotherapy that, against the odds, started to show results.

Three months later, he transitioned to immunotherapy and, to his joy, received his first clean scan on New Year's Eve.

During his treatment, Garcia rediscovered his love for the sky. Told he had little time left, he made it his mission to return to skydiving and BASE jumping. By 2020, he was back in the air, with 575 skydives and 50 BASE jumps under his belt.

Now, five years cancer-free at 31, Garcia's life is a testament to resilience. He works with his family's business, volunteers for cancer organizations and continues to chase the sky, reminding others that deferred dreams can still take flight.

Cancer survivor Donna Scott focuses on fitness to improve her quality of life

THE JOURNEY OF THRIVING

Cancer survivors in the U.S. are increasing. While this growth is a sign of progress, the need for comprehensive survivorship care is more pressing than ever. Many survivors experience lingering physical and psychosocial symptoms that can persist for years, even decades, after treatment. However, according to the National Cancer Institute (NCI), the quality of survivorship care varies significantly, leaving many survivors with unmet needs.

Sylvester has long recognized the importance of addressing these needs. The center's leadership played a pivotal role in the development of new NCI standards for survivorship care. Under the guidance of experts like Frank J. Penedo, Ph.D., associate director of population sciences and director of Cancer Survivorship and Supportive Care and Jessica MacIntyre, D.N.P., APRN, assistant vice president of Advanced Practice Providers, Sylvester has created a robust survivorship program that integrates evidence-based care, including psychosocial services, lifestyle medicine and rehabilitation. "Sylvester's program is unique in Florida," said Dr. Penedo.

Dr. Frank J. Penedo

"We are one of the few centers offering a comprehensive, individualized approach to survivorship."

This program includes specialized wellness clinics tailored to different cancer types, from lymphoma to breast and gastrointestinal cancers. These clinics are designed to help survivors manage their health, including screenings for recurrence, vaccination schedules and support for emotional well-being.

Research is also at the core of Sylvester's survivorship care. As an NCI-designated cancer center, Sylvester is studying patient outcomes and exploring how individual therapies, like music therapy, affect survivors. A focus of Sylvester's research includes how survivorship experiences differ across South Florida's communities.

In addition, Sylvester continues to lead the "Avanzando Caminos" (Leading Pathways) study, a groundbreaking research initiative focused on cancer survivorship in Hispanic/Latino populations. Funded by a $9.8 million grant from the NCI, the study aims to identify the factors contributing to poorer health outcomes and quality of life among Latino cancer survivors. In partnership with the Mays Cancer Center at the University of Texas, this large-scale study strives to improve care and enhance cancer survivorship outcomes.

Through its innovative approach, Sylvester is helping redefine cancer survivorship care, ensuring that survivors not only live longer, but also thrive long after their treatment ends.

MELODIES OF RESILIENCE

Can combining music therapy and mindfulness help cancer patients navigate the emotional and physical challenges of treatment? This is the focus of an innovative study Dr. Penedo and Teresa L. Lesiuk, Ph.D., from the University of Miami Frost School of Music, are leading. The study, supported by a five-year, $2.6 million grant from the NCI and other federal agencies, investigates whether integrating these two disciplines can alleviate depression, anxiety and treatment-related physical symptoms, all of which affect many cancer patients.

The study, which focuses on patients undergoing allogeneic stem cell transplantation, combines mindfulness techniques with music therapy to reduce stress and enhance the immune response. Music therapy has already been shown to improve cognitive function and decrease pain, while mindfulness helps reduce stress and supports emotional well-being.

By tracking both psychological and biological outcomes, Sylvester's researchers hope to establish a direct link between these interventions and improved health outcomes for cancer patients, potentially making this approach a standard part of cancer care.

CHERISHING LIFE

In 2024, Sylvester gathered to honor the triumphs of over 100 cancer survivors at the "Celebration of Life" event. Among the voices that resonated was that of Donna Scott, a breast cancer survivor whose journey from diagnosis to being cancer-free became a reference point for resilience and renewal.

This celebration of personal triumphs gained strength through the transformative power of storytelling. "Rewriting Cancer," a poignant short-film branded-content series by BBC StoryWorks, spotlighted Scott's narrative alongside others, casting a light on the courage and strength of those rewriting the script of survivorship.

Building on this momentum, the spirit of renewal found a resounding echo at the 3rd Annual Sylvester Cancer Survivorship Symposium. Its dual focus – empowering patients and equipping providers – shifted the conversation from "Will you live?" to the deeper, more profound question: "How will you live?" Drs. Penedo and MacIntyre designed the symposium, transforming survivorship into a movement and inspiring new approaches to care and recovery.

"It was humbling and inspiring to witness so many dedicated voices united in the pursuit of thriving beyond cancer," reflected MacIntyre.

REFLECTIONS OF STRENGTH

Rochelle Broder-Singer, a seasoned journalist with more than 25 years of experience in journalism and communications, is using her voice to inspire others through her personal journey with breast cancer. Diagnosed on November 20, 2023, she has navigated her treatment with resilience and optimism, sharing insights to help others facing similar challenges.

Currently in the early survivorship phase, Broder-Singer, Sylvester's first patient columnist, is reflecting on her experience and writing a series of impactful articles for Sylvester.

Her work, written in first-person, offers practical advice and heartfelt perspectives, emphasizing the importance of accurate diagnoses, informed decision-making and the support available to patients and caregivers.

BEAMING BEYOND STADIUM LIGHTS

After two decades on the baseball field, Mervyl Melendez faced a curveball like no other – prostate cancer at 46. Early detection through screening gave him a lifeline. With unwavering faith, he fought back, embracing a new chapter in life after surgery and treatment. Now cancer-free, Melendez celebrates resilience, family and the power of early action, urging others to take charge of their health.

Sylvester patient Mervyl Melendez threw the first pitch at a Marlins game and posed with his doctor, Alan Dal Pra, M.D., medical director of radiation oncology.

EMPOWERING CANCER SURVIVORS

Lifestyle medicine plays a pivotal role in preventing new or recurring cancer. Adopting healthy habits during and after treatment significantly enhances patient outcomes, improving quality of life and reducing the risk of recurrence. But how can health care providers create accessible lifestyle programs tailored to cancer survivors' needs?

Tracy E. Crane, Ph.D., RDN, co-lead of the Cancer Control Program at Sylvester and director of lifestyle medicine, prevention and digital health, is working to answer that question with several initiatives. In addition to launching the High-Risk Lifestyle Medicine, Prevention and Digital Health program, which focuses on helping survivors and their support persons reduce cancer risk through healthy lifestyle behaviors, she and her team began the Precision Oncology Interventions in Nutrition and Training (OnPOINT) clinical trial. This trial seeks to understand how personalized nutrition and exercise approaches can improve wellness after cancer treatment.

The $700,000, three-year OnPOINT study, funded by The Applebaum Foundation and Sylvester, initially focuses on adults treated for breast, prostate and colorectal cancers, which represent more than 50% of cancer survivors in the U.S. The trial involves 300 participants in an eight-week program tailored to their fitness, diet and quality of life. Using wearable fitness data and participant feedback, researchers assess symptoms and group individuals into low-, moderate- or high-complexity categories, providing support ranging from

text-based tools to one-on-one sessions with dietitians and physiologists.

OnPOINT will help develop an algorithm for precise lifestyle interventions, ensuring the right care at the right time. Sylvester's proprietary My Wellness Research tool integrates patient data into care plans, optimizing findings for real-world application. The study will expand to include blood cancer survivors, contributing to long-term health improvements and advancing the field of exercise oncology.

Sylvester also co-leads one of the four trials in the NCI-funded Exercise and Nutrition Interventions to Improve Cancer Treatment-related Outcomes (ENICTO) consortium. Dr. Crane and Matthew Schlumbrecht, M.D., M.P.H., co-director for research operations for Sylvester's Cancer Survivorship program, are guiding Sylvester's involvement. Dr. Crane directs the diet and nutrition working group, while Dr. Penedo leads the patient-reported outcomes working group. Together, they collaborate with Yale University on the Trial of Exercise and Lifestyle in Women with Ovarian Cancer (TEAL), currently recruiting ovarian cancer patients who are beginning chemotherapy. The trial explores whether a prescribed diet and exercise regimen can improve treatment outcomes for ovarian cancer, the leading cause of gynecological cancer death in the U.S.

Dr. Matthew Schlumbrecht

Dr. Crane also continues to co-lead the Lifestyle Intervention for Ovarian Cancer Enhanced Survival (LIVES) trial, collaborates with colleagues on the V Foundation-funded Lifestyle Intervention of Food and Exercise for Lymphoma Survivors (LIFE-L) study and launched an NCI-funded study with the NRG Oncology Group that focuses on the digital health component of Dr. Crane's research. In addition, she's involved with two more studies enrolling participants: FastER, which studies the effects of exercise and fasting on breast cancer, and VITALITY, which examines lifestyle interventions for older cancer survivors and their caregivers.

Dr. Tracy Crane

HOLISTIC PHILOSOPHY

Dr. Crane emphasizes Sylvester's unique approach: "We not only offer traditional social support and psychology, but also art therapy, nutrition and exercise trainers. We study these aspects of survivorship, including lifestyle medicine, in real-time, translating new research directly into clinical practice."

Programs like "Believe in You," which prepares cancer survivors for the Dolphins Cancer Challenge, help build strength and confidence while encouraging survivors to stay active posttreatment. Sylvester also offers survivors an online library of exercise videos for continued support.

By advancing lifestyle interventions and combining research, digital health and personalized care, Sylvester is leading the charge in improving health outcomes for cancer survivors and preventing new cancers, setting a new standard for cancer care.

2024 IMPACT HIGHLIGHTS



JAN.04

MYELOMA: Sylvester researchers found that preventive treatment for cytokine release syndrome prior to teclistamab administration reduces the incidence of this syndrome in multiple myeloma patients, potentially allowing for outpatient care and making the therapy more accessible.



JAN.11

BRAIN CANCER: Sylvester researchers discovered that glioblastoma tumors mimic healthy cells, making them harder to treat. They showed that combining two drugs, vemurafenib and temozolomide, can effectively target these resistant tumors, offering new treatment hope.

JAN.29

CERVICAL CANCER: Sylvester is analyzing the impact of psychological stress and whether it can be mitigated with lifestyle medicine, such as with diet and exercise to help cure cancer.



FEB.01

HEAD AND NECK CANCER: A promising new therapeutic strategy for a challenging set of cancers emerged when Sylvester researchers demonstrated that the drug olaparib, used alone or with another drug, decitabine, can effectively kill certain head and neck cancer cells.

Dr. Lluis Morey

APR.03

GASTRIC CANCER: Sylvester researchers used Game Changer vehicles and mobile labs for a community outreach study to screen for and treat Helicobacter pylori, a major gastric cancer risk factor. Their work focuses on preventing gastric cancer in high-risk populations through early detection.

MAY.21

LEUKEMIA: A Sylvester study found that a leukemia treatment that blocks two proteins, CARM1 and JAK2, works better than treatment that targets only one, offering a promising new approach for leukemia treatment.

MAY.23

BLOOD CANCER: Research from Sylvester revealed that treating high-risk blood cancer patients with stem cells from unrelated donors who are only partially matched can be effective. The use of cyclophosphamide helps improve the success rate, which is advantageous for groups that are typically underrepresented in donor registries.



Dr. Antonio Jimenez Jimenez

JUN.03

SARCOMA: Sylvester researchers are conducting a phase 1 study introducing a fifth-generation KIT inhibitor medicine to humans to treat metastatic gastrointestinal stromal tumors.

Dr. Jonathan Trent

JUL.08

SKIN CANCER: The Bendetson family made a gift to establish the William and Rose Bendetson Skin Cancer Research Endowment in the Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery.

SEP.03

TRANSPLANT CELLULAR THERAPY: The first patient to receive CAR T-cell therapy for non-Hodgkin lymphoma after a bone-marrow transplant at Sylvester is now cancer-free and fully recovered.

SEP.17

PROSTATE CANCER: A Sylvester research team contributed significantly to a study that helped resolve a therapy path for prostate cancer patients who have inherited a specific gene mutation that otherwise shortens survival.



Debi Portela, breast cancer survivor

OCT.01

BREAST CANCER: Sylvester hosted more than a dozen events during breast cancer awareness month in October—walks, talks, luncheons, webinars, football games and fashion shows—promoting early detection, supporting survivors and uniting the community.

OCT.24

PEDIATRIC CANCER: Several pediatric cancer patients at Sylvester attended Taylor Swift's Miami concert, thanks to generous donations from Dolphins Cancer Challenge Foundation board members and other Sylvester supporters, giving the young patients a memorable experience at one of the year's most sought-after concerts.



NOV.04

LYMPHOMA: Sylvester researchers contributed to a study that is transforming Hodgkin lymphoma treatment, demonstrating that adding nivolumab to a mix of chemotherapy drugs outperforms the standard therapy for advanced stages of the disease.

NOV.20



NEUROENDOCRINE TUMORS: Experts in neuroendocrine and gynecologic cancers at Sylvester partnered with industry leaders to begin an investigator-initiated phase 1 clinical trial evaluating novel combination treatment for patients with these types of cancers that have proved resistant to standard therapies.

DEC.03

LUNG CANCER: Researchers at Sylvester foresee that within the next five to 10 years, the field will double down on some of the advancements, notably targeted therapies, that have driven progress.

BRILLIANCE

EXPERTISE THAT POWERS EXCELLENCE

There were exceptional milestones in 2024, where unparalleled knowledge and unwavering dedication radiated from those dedicated to the advancement of cancer research. We made discoveries and shaped the future of oncology through the remarkable contributions of our people.

The K12 Calabresi Clinical Oncology Research Career Development Program continued to nurture the next generation of leaders, including bone marrow transplant researcher Noa Holtzman, M.D., and pancreatic cancer researcher Gretel Terrero, M.D., who joined as new scholars. Their research reflects our mission to translate clinical research into better patient care.

In addition to groundbreaking research and innovation in clinical practice, our commitment to fostering leadership within the cancer care community shined through the new Emerging Leaders Program, led by Sylvester researcher Sophia George, Ph.D., and our partnership with the Miami Herbert Business School. Launched to empower junior and mid-career faculty, the program's first cohort of 12 participants is receiving mentoring that enables them to drive our innovation and lead change in cancer care.

Our researchers embodied the brilliance that defines us, shaping a future where innovation, leadership and compassion converge to redefine cancer care.

Learn About Careers at Sylvester.

THE GIFT OF KNOWLEDGE:

FROM PAIN TO PURPOSE

Solange Sierra, APRN, uses her personal experience to help patients with rare tumors like sarcoma.

"My journey taught me the frustration of navigating a rare diagnosis," Sierra said. "Now, I can reassure patients that they're in the right place for comprehensive care."

Sierra's pain began in her teens, but she dismissed it as a sports injury. By the time she sought medical help, an MRI was inconclusive, and she was advised to "live with the pain." She managed it with over-the-counter painkillers, put her focus on nursing school and pushed through. After earning her nursing degrees from the University of Miami, she discovered a lump on her leg and pursued a diagnosis. This time, her medical knowledge helped her. She was diagnosed with tenosynovial giant cell tumor (TGCT) – a rare, nonmalignant tumor affecting joints and tendons, which was operable and successfully removed. "For the first time in six years, I was pain-free," Sierra recalled.

Now, Sierra works alongside oncologist Gina D'Amato, M.D., treating patients with rare sarcomas. Sarcomas, like TGCT, are often misdiagnosed, with patients frequently dismissed as having muscle strains or minor injuries. Sierra encourages her patients to advocate for their health and keep searching for answers.

"Don't let anyone dismiss your concerns," she urged. Sylvester's specialized sarcoma team is among the best in the nation, treating around 900 new patients annually. "Patients come from around the world to receive treatment at Sylvester," Sierra said. She stressed the importance of raising awareness for rare diseases, which can lead to earlier diagnoses and better outcomes.

NEW FACES, FRESH PERSPECTIVES

With 20 years of experience in stem cell transplantation, oncology and clinical research, Damian Green, M.D., joined Sylvester as chief of the Division of Transplantation and Cellular Therapy and assistant director of translational research in March 2024.

Previously at Fred Hutchinson Cancer Center, Dr. Green's research focuses on blood cancers, particularly multiple myeloma and lymphoma. His work led to the development of innovative immunotherapies targeting CD38, a protein on B cells (white blood cells that produce antibodies to fight infection and disease).

He also pioneered radioimmunotherapy using radiolabeled antibodies and advanced CAR T-cell therapy by enhancing the targeting of B-cell maturation antigen (BCMA) proteins. Although these advancements have improved treatments for blood cancer patients, Dr. Green remains driven to find permanent cures, particularly for multiple myeloma and plans to expand Sylvester's immunotherapy efforts for blood cancers to offer patients a chance at long-term survival and improved quality of life.

After a rigorous national search, Markus Bredel, M.D., Ph.D., was named chairman of the University of Miami Miller School of Medicine's Department of Radiation Oncology. Dr. Bredel joined a team dedicated to delivering precision, patient-centered cancer treatment that was the first in South Florida to use HyperArc™ to treat brain tumors and one of the first in the world to offer ViewRay MRIdian® MRI-guided radiation therapy. Prior to this, he served as the Sharon A. Spencer Distinguished Endowed Chair in Translational Radiation Oncology at the University of Alabama at Birmingham, where he directed brain tumor research and functional brain radiosurgery.

Dr. Bredel has also held faculty positions at Stanford, Northwestern and the University of Freiburg. He is renowned for his research on gliomas and has published extensively in top medical journals. With expertise in advanced radiosurgery, he contributed to the development of the FDA-approved Varian TrueBeam/Edge platform for essential tremor.

UNLOCKING TUMOR MYSTERIES

Anna Lasorella, M.D., director of the Precision Medicine Initiative at Sylvester, is advancing the future of cancer treatment through deep molecular understanding of tumors. Her research, focused on brain cancers like glioblastoma, aims to identify tumor vulnerabilities and tailor treatments based on genetic and molecular characteristics.

A native of Italy, Dr. Lasorella transitioned to scientific research more than 20 years ago after realizing the limitations of conventional treatments in pediatric neuro-oncology. She joined Sylvester in 2022, bringing expertise from Columbia University, where she worked alongside Sylvester Deputy Director Antonio Iavarone, M.D., a leader in neuro-oncology.

In her lab, Dr. Lasorella studies how brain tumors develop, become aggressive and resist treatment. Using patient-derived tumor models, her team analyzes the spatial interactions between tumor and normal cells, seeking new ways to target and treat cancers. Their current focus is on understanding tumor architecture and its impact on immunotherapy resistance.

The Precision Medicine Initiative at Sylvester aims to create personalized tumor models that incorporate a patient's tumor genetics, RNA and methylation profiles, which will guide tailored treatment. Dr. Lasorella's work builds on existing tumor characterization efforts, striving for a more detailed molecular analysis to refine targeted therapies.

CELEBRATION OF EXCELLENCE

Sylvester Director Stephen D. Nimer, M.D., was honored with the American Society of Hematology's 2024 Mentor Award for Basic Science, recognizing his exceptional guidance and mentorship of over 100 hematology trainees. Known for fostering a collaborative environment, he has shaped careers through tailored advice, emphasizing critical thinking and embracing challenges. Dr. Nimer's mentorship continues to impact Sylvester's culture, with his guidance influencing both research and leadership development across the institution.

Three Sylvester faculty, Gilberto Lopes, M.D., M.B.A.; Coral Olazagasti, M.D.; and Tracy Crane, Ph.D., RDN—were selected as mentors for a new ASCO program to assist in fostering a new generation of cancer researchers in Latin America. The yearlong initiative combines clinical training and mentorship to improve regional cancer care, with both in-person and virtual components. Funded by Conquer Cancer, The ASCO Foundation, it aims to improve care within the scholars' communities.

Jashodeep Datta, M.D., associate professor of surgery at Sylvester and DiMare Family Endowed Chair in Immunotherapy, received the prestigious Young Physician-Scientist Award from the American Society for Clinical Investigation. Specializing in pancreatic cancer, Dr. Datta's research focuses on targeting immune cells that fuel tumor resistance. His work drives innovative clinical trials aimed at improving patient outcomes and advancing cancer therapy.

Dr. Rodriguez was recognized with the Patient Educator of the Year award by Cancer GRACE, for empowering patients with vital information. Additionally, she was reelected to the Dade County Medical Association executive board, where she advocates for physician rights, addresses issues like burnout and billing transparency and supports young physicians through her leadership in the Physician Leadership Academy.

Sylvester's Radiation Oncology team received the Human Experience (HX) Pinnacle of Excellence Award presented by Press Ganey.. This reflects a culture focused on patient care and collaboration, supported by leading-edge technology like proton therapy and MRI-guided radiation therapy.

Destiny Tiburcio, a Ph.D. student at the University of Miami, used her HHMI Gilliam Fellowship to study phthalates' effects on the blood-brain barrier and cancer defenses. Mentored by Michal Toborek, M.D., Ph.D., professor and vice-chair for research for the Department of Biochemistry and Molecular Biology, her research explored how these chemicals disrupt circadian rhythms.

MENTORSHIP IN MOTION

Brooke Crawford, M.D., division chief of orthopaedic oncology and a sarcoma surgeon at Sylvester, and her mentor, Francis Hornicek, M.D., also a sarcoma surgeon and professor and chair of the Department of Orthopaedics, have maintained a strong professional bond since Dr. Crawford's fellowship at Massachusetts General Hospital. Both are dedicated to the treatment of sarcoma and other complex cancers of the musculoskeletal system. Dr. Crawford praised Dr. Hornicek for his exceptional mentorship, noting his ability to guide junior faculty and foster their growth. Their relationship now extends to Sylvester, where Dr. Hornicek continues to mentor Dr. Crawford, who has taken on the role of guiding residents and junior faculty. Their shared commitment to mentorship in the cancer field fosters a culture of support and professional development across generations.

SHINING STARS

The Sylvester Stars Employee Recognition Program is headed by Sylvester's Board of Governors. Launched in 2021, it recognizes employees who have gone above and beyond. These 2024 honorees represent just a few of the many who bring purpose and passion to our mission every day.

Members of the University of Miami Health System Multi-Specialty Clinic Team (from left): Katherine Alvarez, RN; Marlen Figueroa, medical assistant; Asiel Roque, RN; and Adriana Alvarez, oncology social worker

Migdia Perez, APRN

Samuel Tablada, respiratory therapist

Members of Sylvester's Radiation Therapy Team (from left): Jessica Law, Catherine LeDroux, Gerardo Sanchez, Monica Martinez, Brandon Kerby, Xaviera Martin, Michelait Pierre, Sharlyn Montoya, Lina Botero and Ashley Braam

Karen Sanchez, head and neck cancer social worker

Melissa Rondon, nurse manager

RADIANCE

EMPOWERING WORK THAT UPLIFTS COMMUNITIES

Our ongoing efforts continue to illuminate new paths for access to health care and resilience through committed advocacy and strengthened education.

In 2024, we held hundreds of community events from Monroe, Miami-Dade, Broward and Palm Beach Counties to provide free cancer screenings, health services and education to the community. The event blended expert insights with wellness activities.

Building on Sylvester's commitment to health access, our focus on occupational cancer risks took center stage at the sixth annual International Firefighter Cancer Symposium. With more than 1,300 participants, the event addressed the unique cancer threats first responders face and the science needed to drive change. Funded by the State of Florida, the Sylvester Firefighter Cancer Initiative—led by Erin Kobetz, Ph.D., M.P.H., associate director for community outreach and engagement at Sylvester—aims to reduce cancer risk among firefighters through research, education and policy. From minimizing harmful exposures in gear to tackling emerging hazards, the initiative is advancing evidence-based solutions to protect those who protect us.

Extending our reach across Florida, we partnered with Moffitt Cancer Center and University of Florida Health Cancer Center to distribute grants that empowered local communities to implement innovative cancer prevention and education programs. These efforts, ranging from smoking cessation initiatives to interactive exhibits, like an inflatable giant colon, engaged high-risk populations, inspired action and fostered greater awareness about cancer risks and prevention strategies.

Through collaboration, innovation and an unwavering focus on community, our work in 2024 radiated as a transformative force, advancing a healthier future for all.

Be Part of Our Events.

THE GIFT OF CONNECTION:

UNITED IN RESILIENCE

Cancer at any age is challenging, but for people ages 15 to 39, balancing a diagnosis with life's milestones like finishing school, starting a family and maintaining relationships, adds an extra layer of complexity. There is no clear path after cancer treatment, and questions and uncertainties linger.

Ashlee Cramer supported her husband, who succumbed to cancer, and later, her son, Michael, on his cancer journey. After finishing treatment for hepatosplenic T-cell lymphoma at Sylvester, Michael still faced challenges with graft-versus-host disease, a common complication of bone marrow transplants. Despite the struggle, Ashlee found solace in the community of patients and families sharing similar experiences.

Survivors and caregivers often don't have time to reflect until after treatment ends: "In hectic moments, we have adrenaline, but when the downtime comes, it all rushes back," Ashlee shared.

The Cramers are part of Sylvester's Patient and Family Advisory Council (PFAC), working to improve care and support for families like theirs. Ashlee also began collaborating with UHealth to create a PFAC for caregivers. The mother and son view life after cancer as a second phase of their journey, taking each day one moment at a time. They also find beauty in their brokenness, sharing their story through blogs, podcasts and social media to inspire others. Michael said, "It's meaningful to find purpose in your struggles."

The Cramers have learned six important aspects of post-cancer survivorship: finding a supportive community, considering therapy, discovering new purposes, accepting life's imperfections, recognizing survivor's guilt and avoiding comparisons with peers. As Ashlee reflected: "You don't bounce back; you bounce forward."

CLOSER TO HOME

In 2024, the Department of Radiation Oncology deepened its commitment to the people and communities we proudly serve—standing not only as a leader in cancer care, but as a trusted partner on life's most difficult journeys. Every advancement was guided by a simple but powerful mission: to expand access, earn trust and deliver the kind of care we'd want for our own families.

Under the thoughtful leadership of Markus Bredel, M.D., we welcomed new faculty and residents who bring fresh ideas and a shared belief in compassionate, community-rooted care. The opening of our new Doral location was a proud milestone—making world-class radiation oncology more accessible to patients and families closer to home.

At every one of our sites, it's our people who make the difference. Their dedication and warmth helped us earn our fifth consecutive Human Experience (HX) Pinnacle of Excellence Award from Press Ganey, a recognition that reflects the trust and gratitude of the patients who walk through our doors.

Our team's impact reached the national stage, too. At the 2024 American Society for Radiation Oncology meeting, Brandon Mahal, M.D., M.P.H., presented at the Presidential Symposium, sharing research focused on closing care gaps and improving outcomes.

With two new satellite clinics and the Kenneth C. Griffin Cancer Research Building opening in 2025, we carry our mission forward: to serve with purpose and bring healing closer to home for more members of our community.

Dr. Markus Bredel

A PERSONAL MISSION

For Dr. Brandon Mahal, appointed vice chair of Sylvester's Department of Radiation Oncology in 2024 and program director of the clinical residency training program, addressing cancer is deeply personal. Growing up in Madera, Calif., he witnessed the toll cancer takes on families—especially after losing his grandmother to lung cancer.

Despite being raised in a neighborhood marked by hardship, Dr. Mahal's determination led him to UCLA and Harvard Medical School. Initially drawn to cancer surgery, he found his calling in radiation oncology during a clinical rotation, because of its technology, precision and patient connection.

As part of an ongoing effort to reduce prostate cancer care, Dr. Mahal contributes to the Game Changer initiative in Miami—a community-based program that deploys mobile vans to provide free screenings in high-risk neighborhoods. In 2024 alone, 424 men were screened through the program; 40 had abnormal results and were connected to timely, appropriate follow-up care.

Dr. Brandon Mahal

ECHOES OF COMPASSION

Bereavement is a significant public health issue, with those grieving facing increased risks for mental health challenges, heart disease, cancer and even death. In a paper in *The Lancet Public Health*, researchers from Sylvester and other institutions stressed the urgent need for greater investment in grief support services, particularly in the wake of the COVID-19 pandemic, rising suicide rates and global conflicts, which have exacerbated bereavement-related suffering.

The paper introduced a transitional bereavement care model, advocating for integrating bereavement services into health care organizations and community-based support. This model aims to ensure that families receive continuity of care and emotional support following a loved one's death.

The researchers emphasized the need for health systems to not only improve their own bereavement services, but to also help build community resources, creating "compassionate communities" that can offer ongoing support.

Wendy Lichtenthal, Ph.D., an NIH-funded researcher and founding director of Sylvester's Center for the Advancement of Bereavement Care, was the corresponding author of the paper. She called for a paradigm shift in how health care professionals and institutions view bereavement care and highlighted the importance of education and training in grief support. The model proposed in the paper outlines key pillars, including preventive bereavement care, resource allocation and community involvement. Sylvester's center aims to lead in implementation of these pillars, serving as a model for grief-informed health care systems.

Wendy Lichtenthal, Ph.D.

A VOICE FOR YOUNG SURVIVORS



At 16, Braulio Hernandez was diagnosed with stage 3 Hodgkin lymphoma. After undergoing intensive chemotherapy at Sylvester and treatment at alex's place, he has been cancer-free for five years. His journey through treatment, marked by leading-edge research and compassionate care, inspired him to advocate for increased funding for childhood cancer research and safer, more effective treatments. Now a film student at the University of Southern California, Hernandez is passionate about raising awareness about the need for treatments specifically designed for children.

He believes that young patients deserve therapies that not only fight cancer but also protect their futures from harmful long-term side effects.

BRIDGES OF LIGHT AND LAND

ART IS MEDICINE

An inspiring new art exhibit opened at Sylvester for patients, caregivers and visitors. Located in the atrium of Sylvester's main building, the "Art is Medicine" installation features photography and artwork that span the vibrant landscapes of South Florida and Brazil, creating a bridge between cultures and showcasing the intersection of art, science and patient care. The exhibit is titled "Bridge to Bahia," named for the northeastern Brazilian state that serves as the inspiration for many of the pieces.





One of the exhibit's unique features is its integration with Sylvester's scientific community. A QR code displayed with the artwork links to faculty profiles highlighting bidirectional scientific collaborations, education and patient care.

The exhibit includes works from Sylvester's Patient, Faculty, Staff and Community Arts Challenge, which brings together the creativity of the individuals connected to the institution.

The exhibit's photography, which captures stunning images of Brazilian landscapes, warms the hearts of visitors. It honors the creativity of the community and celebrates the contributions of Sylvester's faculty and trainees from Brazil.

The artwork is not just for visual enjoyment – it serves a therapeutic purpose, as research has shown that viewing nature can significantly improve mental and physical well-being.

"Art has the power to ground us," said Lara Traeger, Ph.D., a clinical psychologist at Sylvester. "For cancer patients, images of tranquil landscapes or vibrant gardens can reduce anxiety and stress, lower heart rates and even increase focus and attention."

Dr. Denise Pereira

Dr. Gilberto Lopes

This art installation, therefore, is not just a display but also a sanctuary of peace that can uplift the spirit of anyone who interacts with it.

Curated by Desert Horse-Grant, Sylvester's chief transformation officer, the exhibit aims to create a place of calm and hope. The carefully selected pieces represent destinations that many dream of visiting, providing a momentary escape from the stress of treatment. "We hope that this exhibit can transport people to a place of peace and wonderment," Horse-Grant said.

The exhibit is a powerful reminder of Sylvester's work, from its community impact in South Florida to its research and patient care. This is evident in the work of Sylvester's faculty, such as Denise Pereira, M.D., a Brazilian-born physician who completed her medical training through Sylvester's Harrington Medical Training Programs. Dr. Pereira, associate professor of clinical medicine in the Division of Transplantation and Cellular Therapy at Sylvester, has helped expand the use of stem cell therapy, offering leading-edge treatments to the local community.

Faculty members like Gilberto Lopes, M.D., associate director of global oncology, are leading efforts to improve cancer care through mentoring and educational exchanges. These collaborations extend into Sylvester's research endeavors, such as the groundbreaking studies on gastric cancer Wael El-Rifai, M.D., Ph.D., associate director of basic science and associate vice chair of surgery at Sylvester, is conducting.

Dr. Wael El-Rifai

BEACON

LEGACY OF GIVING

THAT DRIVES

CURES

This year, extraordinary acts of generosity and resilience have come together to shape the future of cancer care in transformative ways. Kenneth Griffin's $50 million gift for the construction of the Kenneth C. Griffin Cancer Research Building stands as a cornerstone of this momentum—accelerating innovation, collaboration and the pursuit of cures for generations to come.

Also central to this progress is Jayne S. Malfitano, chair of the Board of Governors at Sylvester. Her leadership has helped steward more than $62 million from the Harcourt M. and Virginia W. Sylvester Foundation, fueling groundbreaking research and expanding community outreach through programs like the Game Changer vehicles. Honored as a Health Care Hero by the Greater Miami Chamber of Commerce, Malfitano continues to be a driving force behind Sylvester's mission.

Adding to this wave of support, the Batchelor Foundation awarded a $9.5 million gift to accelerate breakthrough treatments—and potential cures—for children with cancer, offering renewed hope to families through innovative research and comprehensive survivorship programs.

Alongside these foundational commitments, a series of major gifts is propelling advances across multiple areas of research and care. A $5.4 million bequest from Barry Farber is accelerating efforts in prostate and lung cancers—two areas of urgent need. Professional baseball player Anthony Rizzo's $900,000 pledge builds on his long-standing support of lymphoma research, honoring the care that once saved his life. The Bendetson family's $250,000 gift established the William and Rose Bendetson Skin Cancer Research Endowment, supporting promising new approaches to skin cancer treatment.

Other contributions reflect deeply personal commitments. Judith Engel's $50,000 gift created the Judith and Steven Engel Research and Education Endowment in Head and Neck Surgery, ensuring continued progress in a vital field. The Beyer Family Skin Cancer Prevention and Control Initiative, launched by Anthony Beyer, will provide targeted education to improve skin cancer prevention strategies across South Florida. Antonio Gonzalez, inspired by his own cancer journey, is supporting lung cancer research to help close critical gaps in care. And in a powerful tribute to Sean Stone, his family has raised funds in his memory to advance pioneering research and offer hope to others.

These visionary donors and leaders are shaping a future where cancer care is defined by innovation, compassion and a relentless pursuit of progress, creating a legacy that will endure for years to come.

Support Us.

TIRELESS FUNDRAISER

Marlene Berg, a University of Miami alumna, has spent her life supporting medical research and patient care. "I believe that everybody should do all they can to help their community and make this a better world," Berg said.

Berg has done just that for most of her life. In 1974, she was one of the original "7 Babes" who founded Project: New Born, a nonprofit organization that supports neonatology research and programs at UHealth. Berg is also a board member of the Diabetes Research Institute Foundation and the founder of E.R.A.S.E. Diabetes.

Nearly four decades ago, she and a group of friends started Cancer Link, a project near and dear to her heart. The all-volunteer group raises funds — more than $4 million to date — to support breast cancer research, education and early detection at Sylvester.

"My vision is a future without breast cancer because all of us have been touched by this deadly disease one way or another," said Berg, who has had two relatives diagnosed with the disease. "While there have been tremendous advances over the years, we still have a long way to go. Cancer Link will not stop fundraising until there is a cure."

Each October, in recognition of breast cancer awareness month, Berg and the Cancer Link volunteers host a luncheon that funds generous grants that allow Sylvester scientists to perform innovative cancer research and pursue novel treatments. Cancer Link also hosts a golf tournament and smaller events to support its efforts.

TRANSFORMATIONAL GIFT

The journey to curing cancer has always been a marathon, characterized by both progress and setbacks. But a transformative $50 million donation to Sylvester is poised to significantly accelerate efforts to combat the disease. This landmark gift, provided by philanthropist Kenneth C. Griffin, is funding the construction of the new, 244,000-square-foot Kenneth C. Griffin Cancer Research Building. This 12-story facility will enhance Sylvester's research capacity and play a pivotal role in the advancement of cancer treatment.

As the only National Cancer Institute-designated cancer center in South Florida, Sylvester stands at the forefront of cancer care and research. Griffin's donation will help the center double its research footprint, offering state-of-the-art laboratories and clinical spaces that will attract top scientists and expand access to clinical trials. The expanded facilities will allow Sylvester to better collaborate across disciplines, accelerate the development of new therapies and create leading-edge treatment opportunities for patients.

The Kenneth C. Griffin Cancer Research Building will foster collaboration by bringing together researchers and clinicians in a shared space. This co-location of laboratory researchers with clinicians will speed up the translation of scientific discoveries into real-world treatments for patients.

Griffin's donation is a continuation of his longstanding philanthropic commitment to

science and medicine. As the founder and CEO of Citadel, Griffin has been dedicated to supporting efforts that drive progress in health care and medical research. His gift to Sylvester reflects his belief in the importance of advancing cancer research and improving patient care. This generous contribution will not only support the research infrastructure but also improve patient outcomes by enabling access to the latest treatments and clinical trials.

One of the key impacts of the new building will be its expansion of clinical trial opportunities, particularly phase 1 trials. These trials offer patients early access to novel treatments that may not be available through other health care facilities. With the increased research space, Sylvester will be able to serve more patients, offering them opportunities to participate in clinical studies that could lead to breakthroughs in cancer treatment.

The new facility will also enhance Sylvester's commitment to improving the quality of life for cancer patients during treatment. Its focus on total-body wellness will provide comprehensive care that addresses not only the disease but also the emotional and physical well-being of patients.

Additionally, the building will incorporate state-of-the-art technologies like machine learning, which will be used to accelerate the development of targeted therapies and personalized treatment plans for individual patients.

Griffin's gift is not just a financial contribution—it is a powerful statement of belief in Sylvester's vision. Stephen D. Nimer, M.D., director of Sylvester, called the donation "trajectory-changing,"

highlighting its importance in ensuring that the center continues to be a leader in the fight against cancer. By supporting Sylvester, Griffin is directly contributing to the ongoing search for a cure and the advancement of cancer care. His donation represents a step forward in making the dream of a cancer-free world a reality, offering hope to patients and families around the globe.

COMMITMENT TO A CURE

Continuing a remarkable relationship more than seven decades in the making, in 2024, The Pap Corps Champions for Cancer Research presented a ceremonial check for $3.9 million to Dr. Nimer, director of Sylvester, during its annual president's meeting May 22 in Boca Raton, Fla.

Thanks to the tireless work of its volunteers, The Pap Corps Champions for Cancer Research's annual donation to Sylvester continues the pursuit of life-changing treatments and improved quality of life for cancer patients worldwide.

South Florida's Largest Volunteer Fundraising Organization

Named after George Papanicolaou, M.D., Ph.D., who introduced the Pap smear in 1928, The Pap Corps was started in 1952 by five visionary women driven by the lack of early detection and treatment of cancer.

Today, it is South Florida's largest volunteer fundraising organization, with more than 22,000 members and 52 chapters, and has raised more than $110 million for cancer research at Sylvester.

"Cancer is a disease that affects everyone, young and old alike," said Sally Berenzweig, CEO of The Pap Corps. "Our goal is to help create a world without cancer. Thanks to the efforts of over 20,000 members who are Champions for Cancer Research, we have raised crucial funds to support groundbreaking research and life-saving treatments at Sylvester. Together, we will find a cure."

"We look forward to accomplishing many more important things together with The Pap Corps with our joint focus on cancer research and the well-being of our patients," said Dr. Nimer.

A Historic $50 Million Pledge

The donation is part of The Pap Corps' landmark 2016 pledge of $50 million to Sylvester, which named Sylvester at Deerfield Beach as The Pap Corps campus. A portion of this year's gift will be used for research into pediatric and adult blood and brain cancer, sarcoma and melanoma.



Left to right: Craig Moskowitz, M.D., physician-in-chief for the Oncology Service Line at Sylvester; Susan Dinter, chair of The Pap Corps' Board of Directors; Stephen D. Nimer, M.D., Sylvester director; Jayne Malfitano, chair of the Board of Governors at Sylvester; and Sally Berenzweig, CEO of The Pap Corps

Sylvester is South Florida's only NCI-designated cancer center. Dr. Nimer, who is also the executive dean for research and professor of medicine, biochemistry and molecular biology and the Oscar de La Renta Endowed Chair in Cancer Research at the University of Miami Miller School of Medicine, thanked the volunteers for standing behind Sylvester in this groundbreaking effort.

"Our members are the reason we are successful, because of their dedication and determination to eradicate this terrible disease," said Susan Dinter, chair of The Pap Corps. "We are proud to partner with Sylvester and will continue to support its research efforts as we have for 72 years."

HOPE IN ACTION

At the 2024 ESPY Awards, tennis legend and philanthropist Serena Williams announced the V Foundation for Cancer Research's groundbreaking 10-year, $30 million partnership with the Dolphins Cancer Challenge (DCC) to fund cancer research at Sylvester. This historic collaboration will support the Stuart Scott Memorial Cancer Research Fund, with the goal of improving cancer treatment nationwide.

This partnership represents the V Foundation's largest fundraising effort to date and builds on the success of the Stuart Scott Fund, which has awarded nearly $16 million to cancer researchers. The funding will support a range of innovative projects, including those focused on aggressive B-cell lymphoma, colorectal cancer, pancreatic cancer and T-cell malignancies, led by prominent researchers, such as Jay Spiegel, M.D., Peter Hosein, M.D., Jashodeep Datta, M.D. and Alejandro Villarino, Ph.D. This collaboration is set to make significant strides in cancer prevention, treatment and research.

Serena Williams announced the V Foundation and DCC's commitment to Sylvester cancer research

RAISING THE BAR TOGETHER

The Dolphins Cancer Challenge (DCC) continues to make a profound impact on cancer research, with its XIV edition in February 2024 surpassing expectations.

Under the theme "One Team, One Fight," the event broke records and raised more than $12 million for Sylvester. While the 2024 event fulfilled the Miami Dolphins' $75 million commitment, the fundraising will continue for years to come.

The 2024 event brought together 6,702 participants, including Dolphins players, and featured bike rides in honor of Hall of Fame players, along with a 5K race through the Miami International Autodrome.

Strategic partnerships have played a crucial role in this success. The DCC, in collaboration with the Children's Tumor Foundation (CTF), co-funded a $1.7 million study to enhance treatments for neurofibromatosis.

Alongside StacheStrong, DCC committed $1 million to advance brain cancer research, while an $8.1 million partnership with the American Cancer Society (ACS) aims to address cancer in South Florida.

Javier Sanchez, the executive director of DCC and a University of Miami alumnus, has been instrumental in guiding the event's growth. His leadership, alongside the expertise of Dr. Nimer, has helped propel DCC's success, advancing cancer research and pushing the boundaries of what can be achieved. Under this collaborative leadership, the DCC continues to raise the bar in advancing cancer research and improving patient outcomes.

DCC XIV (2024)

#1
TEAM FUNDRAISING EVENT IN THE NFL

6,698
PARTICIPANTS

$12M
RAISED

$75M+
RAISED SINCE 2010

Sylvester Director, Dr. Stephen D. Nimer (center); Stuart A. Miller, chair of the UHealth Board of Directors (second from left); and Craig Robins, Sylvester Board of Governors member (second from right), pictured with fellow riders after completing the 99-mile Jason Taylor Ride at DCC XIV



Stephen M. Ross, chairman of the board and managing general partner of the Miami Dolphins

Dan Marino, Hall of Fame Miami Dolphins quarterback and special advisor to the vice chairman, president and CEO of the Miami Dolphins (left); Tom Garfinkel, vice chairman, president and CEO of the Miami Dolphins (center); and Nat Moore, former Miami Dolphins player and senior vice president of special projects, alumni relations and advisor to the vice chairman, president and CEO of the Miami Dolphins (right)

BOARD OF GOVERNORS

Jayne S. Malfitano*
Chair
President and Director, Harcourt M. and Virginia W. Sylvester Foundation

Miguel G. Farra, CPA, J.D.
Vice Chair
South Florida Tax Managing Partner, BDO

Jon Batchelor**
Vice Chair
Trustee, Batchelor Foundation

Jose Bared**
Former Executive Officer and Board Chairman, Farm Stores Corporation

Jennifer Stearns Buttrick
Of Counsel and Director of Pro Bono & Community Involvement, Stearns Weaver Miller

Adam E. Carlin***
Managing Director, Morgan Stanley Private Wealth Management

Susan Diamond
Philanthropist and Officer, Jon and Susan Diamond Family Foundation

Susan Dinter
Chair, Board of Directors, Pap Corps Champions for Cancer Research

John Elwaw
Managing Director, Wealth Management, Financial Advisor, Senior Portfolio Manager, Elwaw/Cavalieri Group, Morgan Stanley

Eric Feder
President, Len[x]

Paul Feinsilver
Chairman of the Board, FMSbonds, Inc.

Tom Garfinkel
Vice Chairman, President and Chief Executive Officer, Miami Dolphins

Saul Gilinski
Chairman & Chief Executive Officer, Lyfe Group Co.

W. Jarrard Goodwin, M.D.
Emeritus Professor, Department of Otolaryngology, University of Miami Miller School of Medicine

Elizabeth Jenkins
Chief Operating Officer and Coach, Crossfit VICE

Alan Kluger
Managing Partner, Kluger, Kaplan, Silverman, Katzen & Levine PL

Kinga Lampert
Co-Trustee, Lampert Foundation

James LeFrak
Vice Chairman and Managing Director, LeFrak

Marc Nachmann
Global Head of Assets & Wealth Management, Global Markets Division, Goldman Sachs

Craig Robins
Chief Executive Officer and President, Dacra

Joan Scheiner*
Community Organization and Development Volunteer

Lally Weymouth
Senior Associate Editor, Washington Post

* Current member of the University of Miami Board of Trustees and the University of Miami Health System Board of Directors.

** Current Emeriti Member of the University of Miami Board of Trustees.

*** Former Sylvester Board of Governors chair and current member of the University of Miami Board of Trustees.

EXECUTIVE LEADERSHIP

Stephen D. Nimer, M.D.
Director, Sylvester Comprehensive Cancer Center
Oscar De La Renta Endowed Chair in Cancer Research
Executive Dean for Research, University of Miami Miller School of Medicine
Professor of Medicine, Biochemistry and Molecular Biology, University of Miami Miller School of Medicine

Antonio Iavarone, M.D.
Deputy Director, Sylvester Comprehensive Cancer Center
Professor of Neurology, University of Miami Miller School of Medicine

Craig H. Moskowitz, M.D.
Physician in Chief, Oncology Service Line, Sylvester Comprehensive Cancer Center
Professor of Medicine, University of Miami Miller School of Medicine

Lazara Pagan, M.S.N
Sr. Associate Vice President, Oncology Services, Sylvester Comprehensive Cancer Center, UHealth, University of Miami Miller School of Medicine

Alvaro J. Alencar, M.D.
Chief Medical Officer, Sylvester Comprehensive Cancer Center
Associate Professor of Medicine, University of Miami Miller School of Medicine

Rhonda Curry
Chief Marketing and Communications Officer, Sylvester Comprehensive Cancer Center

Desert Horse-Grant
Chief Transformation Officer, Sylvester Comprehensive Cancer Center

Javier Milian
Associate Vice President, Oncology Satellite Operations and Recruitment, Sylvester Comprehensive Cancer Center

Jesse Rodriguez M.S., M.H.A
Assistant Vice President, Medical Development and Alumni Relations, University of Miami Health System

Jean T. Stennett, M.P.A.
Assistant Vice President, Research Operations, Sylvester Comprehensive Cancer Center

Lauren Whitmore, M.A.
Assistant Vice President and Associate Director, Research Administration, Sylvester Comprehensive Cancer Center

ASSOCIATE DIRECTORS

Kerry L. Burnstein, Ph.D.
Associate Director, Education and Training, Sylvester Comprehensive Cancer Center
Professor and Chair of Molecular and Cellular Pharmacology, University of Miami Miller School of Medicine

Wael El-Rifai, M.D., Ph.D.
Associate Director, Basic Science, Sylvester Comprehensive Cancer Center
Professor and Associate Vice Chair, Department of Surgery, University of Miami Miller School of Medicine

Maria E. Figueroa, M.D.
Associate Director, Translational Research, Sylvester Comprehensive Cancer Center
Professor, Department of Biochemistry and Molecular Biology, University of Miami Miller School of Medicine

Sophia George, Ph.D.
Associate Professor of Obstetrics, Gynecology and Reproductive Sciences, Division of Gynecologic Oncology, University of Miami Miller School of Medicine

George S. Grills
Associate Director, Shared Resources, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine

Erin Kobetz, Ph.D., M.P.H.
Chief Health Equity Officer and Vice President for Health Equity, University of Miami
Associate Director, Community Outreach and Engagement, Sylvester Comprehensive Cancer Center
John K. And Judy H. Schulte Senior Endowed Chair in Cancer Research
Professor of Medicine, Public Health Sciences and Obstetrics and Gynecology, University of Miami Miller School of Medicine

Frank J. Penedo, Ph.D.
Associate Director, Population Sciences, Sylvester Comprehensive Cancer Center
Co-Leader, Cancer Control Research Program, Sylvester Comprehensive Cancer Center
Director, Cancer Survivorship Program, Sylvester Comprehensive Cancer Center
Professor of Psychology and Medicine, University of Miami Miller School of Medicine

Stephan Schürer, Ph.D.
Associate Director, Data Science, Sylvester Comprehensive Cancer Center
Director, Digital Drug Discovery, Institute for Data Science and Computing, University of Miami
Professor of Pharmacology, University of Miami Miller School of Medicine

Jonathan Trent, M.D., Ph.D.
Associate Director, Clinical Research, Sylvester Comprehensive Cancer Center
Co-Director, Musculoskeletal Center, Sarcoma Medical Research Program, Sylvester Comprehensive Cancer Center
Professor of Medicine, University of Miami Miller School of Medicine

PROGRAM LEADERS

Tracy Crane, Ph.D., R.D.N.

Co-Leader, Cancer Control Research Program, Sylvester Comprehensive Cancer Center

Assistant Director for Faculty Development, Sylvester Comprehensive Cancer Center

Associate Professor of Medicine, University of Miami Miller School of Medicine

C. Ola Landgren M.D., Ph.D.

Co-Leader, Translational and Clinical Oncology Program Research Program, Sylvester Comprehensive Cancer Center

Chief of Myeloma Program, Sylvester Comprehensive Cancer Center

Professor of Medicine, University of Miami Miller School of Medicine

David Lombard, M.D., Ph.D.

Co-Leader, Cancer Epigenetics Research Program, Sylvester Comprehensive Cancer Center

Professor of Pathology and Laboratory Medicine, University of Miami, Miller School of Medicine

Jaime Merchan, M.D.

Co-Leader, Translational and Clinical Oncology Research Program, Sylvester Comprehensive Cancer Center

Director, Phase 1 Clinical Trials Program, Sylvester Comprehensive Cancer Center

Professor of Medicine, University of Miami Miller School of Medicine

Frank J. Penedo, Ph.D.

Associate Director, Population Sciences, Sylvester Comprehensive Cancer Center

Co-Leader, Cancer Control Research Program, Sylvester Comprehensive Cancer Center

Director, Cancer Survivorship Program, Sylvester Comprehensive Cancer Center

Professor of Psychology and Medicine, University of Miami Miller School of Medicine

Priyamvada Rai, Ph.D.

Co-Leader, Tumor Biology Research Program, Sylvester Comprehensive Cancer Center

Director, Medical School Summer Undergraduate Research Fellowship Program, University of Miami Miller School of Medicine

Professor, Department of Radiation Oncology, University of Miami Miller School of Medicine

Ramin Shiekhattar, Ph.D.

Co-Leader, Cancer Epigenetics Research Program, Sylvester Comprehensive Cancer Center

Chief, Division of Cancer Genomics and Epigenetics, University of Miami Miller School of Medicine

Professor of Human Genetics, University of Miami Miller School of Medicine

Scott Welford, Ph.D.

Co-Leader, Tumor Biology Research Program, Sylvester Comprehensive Cancer Center

Assistant Director for Faculty Development, Sylvester Comprehensive Cancer Center

Professor and Biology Division Chief of Radiation Oncology, University of Miami Miller School of Medicine

SITE DISEASE GROUP LEADERS

Breast Cancer	**Carmen Calfa, M.D.** - Clinical Research **Susan B. Kesmodel, M.D.** - Clinical Lead **Lluis Morey, Ph.D.** - Translational Science Lead
Cutaneous Oncology	**Jose Lutzky, M.D.** - Clinical Research **Jennifer Tang, M.D.** - Clinical Lead **Zelia Correa, M.D., Ph.D.** - Translational Science Lead
Endocrine Tumors	**Mark Jara, M.D.** - Clinical Research **Josefina Farra, M.D., FACS** - Clinical Lead
Gastrointestinal Cancer	**Peter Hosein, M.D.** - Clinical Research **Lorraine Portelance, M.D.** - Clinical Lead **Jashodeep Datta, M.D.** - Translational Science Lead
Genitourinary Cancer	**Marijo Bilusic, M.D., Ph.D.** - Clinical Research **Matthew C. Abramowitz, M.D.** - Clinical Lead **Sanoj Punnen, M.D.** - Translational Science Lead
Gynecological Cancer	**Abdulrahman Sinno, M.D.** – Clinical Research **Aaron Wolfson, M.D.** - Clinical Lead **Mathew Schlumbrecht, M.D.** - Translational Science Lead
Head & Neck Cancer	**Donald Weed, M.D.** - Clinical Research **Stuart Samuels, M.D., Ph.D.** - Clinical Lead **Paolo Serafini, Ph.D.** - Translational Science Lead
Hematology	**Gerald Soff, M.D.** - Clinical Research
Leukemia	**Justin Watts, M.D.** - Clinical Research **Namrata S. Chandhok, M.D.** - Clinical Lead **Justin Taylor, M.D.** - Translational Science Lead
Lymphoma	**Juan Alderuccio, M.D.** - Clinical Research **Craig H. Moskowitz, M.D.** - Clinical Lead **Izidore Lossos, M.D.** - Translational Science Lead
Myeloma	**Dickran Kazandjian, M.D.** - Clinical Research **C. Ola Landgren, M.D., Ph.D.** - Translational Science Lead
Neuro-Oncology	**Macarena De La Fuente, M.D.** - Clinical Research **Michael Ivan, M.D.** - Clinical Lead **Eric Mellon, M.D., Ph.D.** - Translational Science Lead
Pediatric Cancer	**Aditi Dhir, M.D.** - Clinical Research **Warren Alperstein, M.D.** - Clinical Lead **Julio Barredo, M.D.** - Translational Science Lead
Sarcoma	**Jonathan Trent, M.D., Ph.D.** - Clinical Research **Gina D'Amato, M.D.** - Clinical Lead **David Lombard, M.D., Ph.D.** - Translational Science Lead
Thoracic Cancers	**Raphael Yechieli, M.D.** - Clinical Research **Estelamari Rodriguez, M.D., M.P.H.** - Clinical Lead **Taghrid Asfar, M.D.** - Translational Science Lead
Transplant Cellular Therapy	**Amer Beitinjaneh, M.D.** - Clinical Research

OUR LOCATIONS

1. Sylvester Deerfield Beach
   The Pap Corps Campus
2. Sylvester Coral Springs
3. Sylvester Ft. Lauderdale
4. Sylvester Plantation
5. Sylvester Hollywood
6. Sylvester Aventura
7. Sylvester Doral
8. Sylvester Comprehensive Cancer Center - Main Campus
9. Sylvester The Lennar Foundation Medical Center
10. Sylvester Kendall

- Sylvester Cancer Care Coordination And Support Services Office In Naples

OPEN IN 2025

11. Sylvester Comprehensive Cancer Center - Kenneth C. Griffin Cancer Research Building
12. Sylvester Solé Mia

THE EXPERT CANCER CARE I NEEDED WAS CLOSE TO HOME

Only Sylvester had the most advanced treatments I needed for my specific cancer. With an expert team at locations across South Florida, I received the best cancer care — close to home. Now I'm back, enjoying the people and places I've always loved most — and I'm more than ready for what's next.

Sylvester Comprehensive Cancer Center, part of UHealth – University of Miami Health System, is South Florida's only National Cancer Institute (NCI)–designated cancer center.

SYLVESTER COMPREHENSIVE CANCER CENTER
UNIVERSITY OF MIAMI HEALTH SYSTEM

OnlySylvester.com | 844-324-HOPE (4673)

NCI Designated Cancer Center

UNIVERSITY
OF MIAMI

6200 San Amaro Drive
Coral Gables, FL 33146

First-Class Mail
U.S. Postage
PAID
UNIVERSITY
OF MIAMI

SYLVESTER
COMPREHENSIVE CANCER CENTER
UNIVERSITY OF MIAMI HEALTH SYSTEM

NCI
Designated
Cancer Center

Commission
on Cancer®
ACCREDITED PROGRAM

MDS Foundation
CENTER OF EXCELLENCE
DESIGNATED
2024-25

Accredited by
Commission on Cancer®
National Accreditation
Program for
Rectal Cancer

ACR
AMERICAN COLLEGE OF RADIOLOGY
RADIOLOGY

CANCER CENTER
of
EXCELLENCE
Florida
HEALTH

ASCO QOPI®
Certification Program

Find out more at Sylvester.org